...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular cancer therapeutics >Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
【24h】

Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

机译：肿瘤在中国局部晚期或转移性胃或胃食管接线癌中的表达和基因扩增

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

MET and its sole ligand, hepatocyte growth factor (HGF), are promising targets in gastric and gastroesophageal junction cancer. We evaluated whether MET protein expression or MET gene amplification is prognostic for overall survival (OS) in Chinese patients with advanced gastric or gastroesophageal junction cancer. Archival formalin-fixed, paraffin-embedded tumor samples from patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer enrolled in clinical trials at Peking University Cancer Hospital from 2008 to 2010 were assessed for MET and phospho-MET (p-MET) expression by immunohistochemistry and MET amplification by FISH. MET-positive expression was defined as membrane protein staining in >= 25% of tumor cells. MET amplification was defined as MET: centromere 7 ratio >2.0. We tested the association of MET status with clinical characteristics and OS, and also evaluated the association between expression and amplification. One hundred sixty-eight patients were eligible. Of the evaluable samples, 53 of 137 (39%) were MET positive, eight of 134 (6%) were p-MET positive, and eight of 113 (7%) were MET amplified. Neither MET expression nor MET amplification were associated with clinical characteristics, except Lauren classification (P = 0.04); MET amplification was associated with diffuse type. No significant OS difference was observed between MET-positive and MET-negative populations, regardless of first-line chemotherapy received. In 95 evaluable patients, MET expression was significantly associated with MET amplification (P < 0.001); all MET-amplified tumor samples showed some MET expression. In 96 evaluable patients, p-MET positivity was significantly associated with MET amplification (P < 0.001). Further evaluation in larger and independent sample sets is warranted to confirm our findings. (C) 2015 AACR.
机译：满足及其唯一配体，肝细胞生长因子（HGF）是胃和胃食管结癌的靶向。我们评估了蛋白表达或达到基因扩增是否是中国晚期胃或胃食管结癌的整体存活（OS）的预后。在2008年至2010年从2008年到2010年，从2008年到2010年患有不可切除的局部晚期或转移性胃或胃食管癌患者的患有不可切除的局部晚期或转移性胃或胃食管接合癌的石蜡嵌入式肿瘤样品被评估为MET和Photo-Met（P-Met）表达通过免疫组织化学并通过鱼达到扩增。 MET阳性表达被定义为膜蛋白染色> = 25％的肿瘤细胞。相容扩增定义为MET：Centromere 7比例> 2.0。我们测试了临床特征和OS的符合状态的关联，并评估了表达和扩增之间的关联。一百六十八名患者符合条件。在可评估的样品中，337（39％）的53个阳性，134个（6％）的阳性为阳性，113个（7％）的含量增加，扩增。除了Lauren分类外，既不与临床特征有关的表达也没有达到扩增（P = 0.04）;相容扩增与弥漫性类型有关。不管收到的一线化疗如何，达到核阳性和遇见负面群体之间没有显着的操作系统差异。在95名可评估的患者中，MET表达明显与达到扩增有关（P <0.001）;所有MET扩增的肿瘤样品都显示出一些满足的表达。在96名可评估的患者中，P-MET阳性与相容扩增显着相关（P <0.001）。有必要进一步评估较大和独立的样本集，以确认我们的调查结果。 （c）2015年AACR。

著录项

  • 来源
    《Molecular cancer therapeutics》 |2015年第11期|共8页
  • 作者

    Peng Zhi; Li Zhongwu; Gao Jing; Lu Ming; Gong Jifang; Tang En-Tzu; Oliner Kelly S.; Hei Yong-Jiang; Zhou Hui; Shen Lin;

  • 作者单位

    Peking Univ Canc Hosp &

    Inst Dept Gastrointestinal Oncol Beijing 100871 Peoples R China;

    Peking Univ Canc Hosp &

    Inst Dept Pathol Beijing 100871 Peoples R China;

    Peking Univ Canc Hosp &

    Inst Dept Gastrointestinal Oncol Beijing 100871 Peoples R China;

    Peking Univ Canc Hosp &

    Inst Dept Gastrointestinal Oncol Beijing 100871 Peoples R China;

    Peking Univ Canc Hosp &

    Inst Dept Gastrointestinal Oncol Beijing 100871 Peoples R China;

    Amgen Inc Biostat Sci Shanghai Peoples R China;

    Amgen Inc Mol Sci Thousand Oaks CA 91320 USA;

    Amgen Inc Global Dev Shanghai Peoples R China;

    Amgen Inc Med Dept Shanghai Peoples R China;

    Peking Univ Canc Hosp &

    Inst Dept Gastrointestinal Oncol Beijing 100871 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号